X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (101487) 101487
Publication (6652) 6652
Newspaper Article (2313) 2313
Book Review (858) 858
Newsletter (598) 598
Book Chapter (363) 363
Magazine Article (298) 298
Report (271) 271
Government Document (225) 225
Conference Proceeding (149) 149
Trade Publication Article (88) 88
Book / eBook (72) 72
Dissertation (72) 72
Patent (54) 54
Web Resource (30) 30
Data Set (13) 13
Paper (10) 10
Reference (9) 9
Transcript (4) 4
Journal / eJournal (2) 2
Library Holding (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47291) 47291
animals (44480) 44480
male (42403) 42403
index medicus (31686) 31686
female (29739) 29739
rats (22575) 22575
sodium (18644) 18644
adult (16034) 16034
middle aged (13548) 13548
pharmacology & pharmacy (12122) 12122
mice (8755) 8755
aged (8562) 8562
time factors (7887) 7887
sodium chloride - administration & dosage (7069) 7069
dose-response relationship, drug (6624) 6624
analysis (6281) 6281
rats, sprague-dawley (6109) 6109
physiology (5829) 5829
sodium - metabolism (5692) 5692
neurosciences (5639) 5639
research (5433) 5433
blood pressure - drug effects (5400) 5400
rats, wistar (5284) 5284
adolescent (5209) 5209
hypertension (5069) 5069
treatment outcome (4653) 4653
blood pressure (4587) 4587
disease models, animal (4346) 4346
child (4144) 4144
biochemistry & molecular biology (4106) 4106
health aspects (4095) 4095
sodium - urine (3984) 3984
sodium - blood (3929) 3929
rodents (3861) 3861
endocrinology & metabolism (3804) 3804
diet (3794) 3794
administration, oral (3760) 3760
sodium chloride (3641) 3641
physiological aspects (3581) 3581
sodium chloride - pharmacology (3556) 3556
dogs (3464) 3464
surgery (3446) 3446
hydrogen-ion concentration (3435) 3435
care and treatment (3419) 3419
oxidative stress (3416) 3416
toxicology (3413) 3413
risk factors (3391) 3391
medicine (3276) 3276
expression (3169) 3169
article (3143) 3143
proteins (3123) 3123
urology & nephrology (3123) 3123
research article (3105) 3105
double-blind method (3027) 3027
peripheral vascular disease (3014) 3014
medicine & public health (3003) 3003
cardiac & cardiovascular systems (2990) 2990
medicine, general & internal (2977) 2977
blood-pressure (2959) 2959
rats, inbred strains (2927) 2927
in vitro techniques (2915) 2915
metabolism (2907) 2907
inflammation (2890) 2890
drugs (2833) 2833
rat (2787) 2787
medicine, research & experimental (2781) 2781
kidney - drug effects (2780) 2780
potassium (2723) 2723
cell biology (2660) 2660
pregnancy (2639) 2639
rabbits (2604) 2604
hypertension - physiopathology (2573) 2573
sodium, dietary - administration & dosage (2536) 2536
prospective studies (2507) 2507
inhibition (2505) 2505
nutrition & dietetics (2499) 2499
cells (2484) 2484
oncology (2481) 2481
in-vitro (2432) 2432
studies (2417) 2417
clinical neurology (2402) 2402
multidisciplinary sciences (2401) 2401
brain (2388) 2388
kidney - metabolism (2384) 2384
kinetics (2376) 2376
potassium - blood (2296) 2296
therapy (2284) 2284
drug therapy (2281) 2281
sodium-potassium-exchanging atpase - metabolism (2264) 2264
sodium chloride, dietary - administration & dosage (2263) 2263
osmolar concentration (2256) 2256
child, preschool (2224) 2224
calcium (2208) 2208
young adult (2205) 2205
gene expression (2198) 2198
toxicity (2186) 2186
pediatrics (2175) 2175
double-blind (2172) 2172
body weight (2169) 2169
glucose (2162) 2162
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (31) 31
Online Resources - Online (11) 11
Engineering & Comp. Sci. - Stacks (6) 6
UTL at Downsview - May be requested (6) 6
Robarts - Stacks (4) 4
Robarts - Government Pubs (3) 3
UofT at Mississauga - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (2) 2
Thomas Fisher Rare Book - Rare Book (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
University Archives - Archives (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (100437) 100437
Russian (1089) 1089
German (1081) 1081
Japanese (702) 702
French (581) 581
Spanish (316) 316
Chinese (299) 299
Italian (269) 269
Polish (255) 255
Portuguese (99) 99
Dutch (66) 66
Korean (65) 65
Czech (64) 64
Hungarian (61) 61
Ukrainian (61) 61
Danish (55) 55
Norwegian (45) 45
Swedish (39) 39
Bulgarian (25) 25
Croatian (23) 23
Turkish (20) 20
Hebrew (15) 15
Romanian (14) 14
Slovak (14) 14
Finnish (10) 10
Serbian (10) 10
Arabic (5) 5
Lithuanian (5) 5
Persian (5) 5
Icelandic (2) 2
Greek (1) 1
Indonesian (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
Abstract Objective Combination therapy, specifically with aspirin, cholesterol and blood pressure-lowering drugs, substantially reduces the risk of coronary... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
Journal Article
JAMA Internal Medicine, ISSN 2168-6106, 09/2016, Volume 176, Issue 9, pp. 1266 - 1276
Journal Article
Journal of Critical Care, ISSN 0883-9441, 2016, Volume 36, pp. 116 - 124
Abstract Objectives The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients... 
Critical Care | Anticonvulsants | Intensive care | Hemodialysis | Continuous renal replacement therapy | CONTINUOUS VENOVENOUS HEMOFILTRATION | CLINICAL PHARMACOKINETICS | CARBAMAZEPINE INTOXICATION | HIGH-FLUX HEMODIALYSIS | PARTIAL-ONSET SEIZURES | SODIUM VALPROATE | OF-THE-LITERATURE | FELBAMATE MONOTHERAPY | UREMIC PATIENTS | HEMODIAFILTRATION | CRITICAL CARE MEDICINE | Humans | Seizures - drug therapy | Critical Illness | Anticonvulsants - administration & dosage | gamma-Aminobutyric Acid - administration & dosage | Carbamates - administration & dosage | Phenylenediamines - administration & dosage | Seizures - complications | Dose-Response Relationship, Drug | Anticonvulsants - adverse effects | Phenobarbital - administration & dosage | Acute Kidney Injury - complications | Amines - administration & dosage | Dibenzazepines - administration & dosage | Renal Replacement Therapy | Cyclohexanecarboxylic Acids - administration & dosage | Isoxazoles - administration & dosage | Phenytoin - administration & dosage | Fructose - analogs & derivatives | Phenylcarbamates - administration & dosage | Valproic Acid - administration & dosage | Propylene Glycols - administration & dosage | Triazines - administration & dosage | Piracetam - analogs & derivatives | Piracetam - administration & dosage | Acute Kidney Injury - therapy | Ethosuximide - administration & dosage | Fructose - administration & dosage | Acetamides - administration & dosage | Renal Dialysis | Drugstores | Pharmacy | Index Medicus
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 7/2015, Volume 22, Issue 7, pp. 920 - 930
Background Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether... 
blood pressure | Cardiovascular disease | cholesterol | polypill | adherence | prevention | NON-INDIGENOUS PEOPLE | DRUG-THERAPY | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RATIONALE | MEDICATION NONADHERENCE | IMPACT | GAP | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hyperlipidemias - blood | Prospective Studies | Tablets | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Aspirin - administration & dosage | Hyperlipidemias - diagnosis | Polypharmacy | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | General Practice | Sodium Chloride Symporter Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Female | Adrenergic beta-1 Receptor Antagonists - administration & dosage | Blood Pressure - drug effects | Atenolol - administration & dosage | Hypertension - diagnosis | Hyperlipidemias - complications | Cardiovascular Diseases - diagnosis | Lisinopril - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Administration, Oral | Simvastatin - administration & dosage | Hyperlipidemias - drug therapy | Risk Factors | Drugs, Generic - administration & dosage | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Hypertension - physiopathology | Primary Prevention - methods | Hypertension - complications | Aged | Australia | Drug Combinations
Journal Article
Anesthesiology, ISSN 0003-3022, 09/2007, Volume 107, Issue 3, pp. 427 - 436
Background: During the brain growth spurt, the brain develops and modifies rapidly. in rodents this period is neonatal, spanning the first weeks of life,... 
DEVELOPMENTAL NEUROTOXICITY | ENVIRONMENTAL AGENTS | KETAMINE BLOCKS | ANESTHESIOLOGY | SPATIAL MEMORY | PRENATAL ETHANOL EXPOSURE | DEFINED PERIOD | FLUORO-JADE | BRAIN | PERMANENT CHANGES | CELL-DEATH | Anti-Anxiety Agents - administration & dosage | Anesthetics, Intravenous - adverse effects | Apoptosis - drug effects | Male | Receptors, GABA-A | Anesthetics, Combined - adverse effects | Ketamine - administration & dosage | N-Methylaspartate - adverse effects | Ketamine - adverse effects | Anesthetics, Intravenous - administration & dosage | Time Factors | Behavior, Animal - drug effects | Propofol - administration & dosage | Thiopental - administration & dosage | Analgesics - adverse effects | Disease Models, Animal | Animals, Newborn | Diazepam - administration & dosage | Analgesics - administration & dosage | N-Methylaspartate - administration & dosage | Sodium Chloride - administration & dosage | GABA Antagonists - administration & dosage | Maze Learning - drug effects | GABA Antagonists - adverse effects | Brain - drug effects | Drug Synergism | Excitatory Amino Acid Agonists - administration & dosage | Thiopental - adverse effects | Anesthetics, Combined - administration & dosage | Animals | Neurodegenerative Diseases - chemically induced | Excitatory Amino Acid Agonists - adverse effects | Mice | Drug Combinations | Propofol - adverse effects | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Circulation, ISSN 0009-7322, 03/2007, Volume 115, Issue 10, pp. 1211 - 1217
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 2008, Volume 9, Issue 1, pp. 165 - 165
Background: Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document... 
CHONDROITIN SULFATE | OF-RHEUMATOLOGY RECOMMENDATIONS | INTRAARTICULAR HYALURONIC-ACID | EULAR-STANDING-COMMITTEE | TASK-FORCE | GLUCOSAMINE SULFATE | HIP OSTEOARTHRITIS | DOUBLE-BLIND | RHEUMATOLOGY | ORTHOPEDICS | KNEE OSTEOARTHRITIS | AVOCADO/SOYBEAN UNSAPONIFIABLES | Outcome Assessment (Health Care) - methods | Clinical Trials as Topic - statistics & numerical data | Thiophenes - adverse effects | Antirheumatic Agents - administration & dosage | Humans | Anthraquinones - administration & dosage | Thiophenes - administration & dosage | Osteoarthritis - drug therapy | Calcitonin - administration & dosage | Plant Extracts - administration & dosage | Glucosamine - adverse effects | Chondroitin Sulfates - adverse effects | Anthraquinones - adverse effects | Etidronic Acid - adverse effects | Calcitonin - adverse effects | Antirheumatic Agents - adverse effects | Risedronate Sodium | Hyaluronic Acid - adverse effects | Etidronic Acid - analogs & derivatives | Etidronic Acid - administration & dosage | Hyaluronic Acid - administration & dosage | Organometallic Compounds - adverse effects | Glucosamine - administration & dosage | Chondroitin Sulfates - administration & dosage | Organometallic Compounds - administration & dosage | Plant Extracts - adverse effects | Glucosamine | Research | Hyaluronic acid | Drug therapy | Osteoarthritis | Chondroitin | Index Medicus
Journal Article
Investigative Radiology, ISSN 0020-9996, 2017, Volume 52, Issue 7, pp. 396 - 404
Journal Article